Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 7/20 | 0.59 |
| ▸ | POLB | P06746 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.54 |
| ▸ | ARHGEF12 | Q9NZN5 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454817 | 1.00 | KMT2A (0.71) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL2398010 | 0.80 | KMT2A (0.74) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL196142 | 0.80 | KMT2A (0.74) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL12267471 | 0.80 | KMT2A (0.74) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL5445737 | 0.77 | POLB (0.67) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL5445740 | 0.77 | POLB (0.67) | KMT2AMEN1GAAPOLBALDH1A1 | |
| SCHEMBL5455280 | 0.77 | KMT2A (0.74) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL5455273 | 0.77 | KMT2A (0.74) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL5453405 | 0.76 | KMT2A (0.68) | KMT2AMEN1ABL1SRCGAA | |
| SCHEMBL5453408 | 0.76 | KMT2A (0.68) | KMT2AMEN1ABL1SRCGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007506661-A | — | — | 2007-03-22 | — | — | JP | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | claimed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | claimed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20070037846-A1 | Pyrazolidinedione derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-15 | — | — | US | disclosed |
| EP-1638540-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000281-A2 | PYRAZOLIDINEDIONE DERIVATIVES AND THEIR USE AS PLATELET AGGREGATION INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037846-A1 | Pyrazolidinedione derivatives | P2RY1, P2RY4, P2RY2 | KMT2A 4413/4885MEN1 2963/4885ABL1 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.